Evidence map›Paper›PMID 40625086›Full record

ReviewFuture oncology (London, England)2025

Research progress on treatment-associated pneumonitis in lung cancer patients undergoing radiotherapy and immunotherapy.

Caixun Zhang, Youjia Wang, Hanguang Ruan, Vivek Verma, Weimin Xu, Guang Han

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Caixun ZhangDepartment of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Youjia WangDepartment of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Hanguang RuanDepartment of Thoracic Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China.
Vivek VermaDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Weimin XuOtolaryngology Head and Neck Surgery Department, Wuhan Fourth Hospital, Wuhan, Hubei, China.
Guang HanDepartment of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.ORCID 0000-0001-5500-3338

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy and immunotherapy - both important facets of modern cancer treatment - provide therapeutic benefits, but also raise concerns from potential concomitant adverse effects. One such adverse event, treatment-associated pneumonitis (TAP), can cause profound changes in quality of life of patients with thoracic malignancies. The aim of this review is to elucidate the pathogenesis, incidence, risk factors, differential diagnosis, and management of pneumonitis induced by the combination of radiotherapy and immunotherapy for lung cancer.

Indexed as

ImmunotherapyLung NeoplasmsPneumoniaRadiation PneumonitisRadiotherapyHumansImmune Checkpoint InhibitorsIncidenceQuality of LifeRisk FactorsImmune Checkpoint InhibitorsCombinationimmunotherapyLung cancerradiotherapytreatment-associated pneumonitis

Identifiers

PMID40625086
PMCPMC12330258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.